Empiric Antifungal Therapy Is Not Associated with Improved Infectious Outcomes in Penetrating Upper Gastrointestinal Injuries: A Subgroup Analysis of the Surgical Infection Society Multi-Center Observational Study

Abstract

Background:

The role of empiric antifungal therapy in patients with gastrointestinal (GI) perforations because of penetrating trauma remains unclear. Existing literature suggests minimal benefit in non-traumatic GI perforations. This study aimed to evaluate the association between empiric antifungal use and post-operative infectious complications in patients with upper GI perforations because of penetrating trauma.

Methods:

This was a prospective, multi-center cohort study conducted across 15 institutions between August 2021 and January 2024. We included adult patients with upper GI perforations because of penetrating trauma. The primary outcome was organ/space surgical site infection (SSI) within 30 days. Secondary outcomes included superficial and deep SSI, any SSI (superficial, deep, or organ/space), sepsis, pneumonia, return to the operating room, acute kidney injury (AKI), and in-hospital mortality. Multi-variable logistic regression was used to adjust for confounders.

Results:

A total of 173 patients were included, of whom 23.1% (n = 40) received empiric antifungals. There was no significant difference in the rate of organ/space SSI between patients who received antifungals and those who did not (17.5% vs. 9.8%, p = 0.180). Antifungal use was also not associated with any significant difference in superficial, deep, or any SSI rates. On multi-variable analysis, antifungal therapy was not independently associated with reduced risk of organ/space SSI (odds ratio 1.72, 95% confidence interval 0.58–5.07). Patients who received antifungals had higher rates of sepsis, pneumonia, AKI, return to the operating room, and in-hospital mortality.

Conclusions:

Empiric antifungal therapy was not associated with a reduction in organ/space SSI or any SSI, among patients with penetrating upper GI injuries. Trauma patients with upper GI injuries do not appear to benefit from empiric antifungal coverage.

Keywords

empiric antifungals gastrointestinal perforation penetrating trauma surgical site infection

Get full access to this article

View all access options for this article.

References

Fabian

. Prevention of infections following penetrating abdominal trauma. Am J Surg, 1993; 165(2A Suppl):14S–19S; doi: 10.1016/S0002-9610(05)81202-4

Demetriades

, Lakhoo

, Pezikis

, et al. Short-course antibiotic prophylaxis in penetrating abdominal injuries: Ceftriaxone versus cefoxitin. Injury, 1991; 22(1):20–24; doi: 10.1016/0020-1383(91)90154-7

Kirton

, O’Neill

, Kestner

, et al. Perioperative antibiotic use in high-risk penetrating hollow viscus injury: A prospective randomized, double-blind, placebo-control trial of 24 hours versus 5 days. J Trauma, 2000; 49(5):822–832; doi: 10.1097/00005373-200011000-00006

, Dong

, Yao

, et al. Risk factors for postoperative sepsis in patients with gastrointestinal perforation. World J Clin Cases., 2020; 8(4):670–678; doi: 10.12998/wjcc.v8.i4.670

Goldberg

, Anand

, Como

, et al.; Eastern Association for the Surgery of Trauma. Prophylactic antibiotic use in penetrating abdominal trauma: An eastern association for the surgery of trauma practice management guideline. J Trauma Acute Care Surg, 2012; 73(5 Suppl 4):S321–S325; doi: 10.1097/TA.0b013e3182701902

Bozorgzadeh

, Pizzi

, Barie

, et al. The duration of antibiotic administration in penetrating abdominal trauma. Am J Surg, 1999; 177(2):125–131; doi: 10.1016/S0002-9610(98)00317-1

de Ruiter

, Weel

, Manusama

, et al. The epidemiology of intra-abdominal flora in critically ill patients with secondary and tertiary abdominal sepsis. Infection, 2009; 37(6):522–527; doi: 10.1007/s15010-009-8249-6

Carneiro

, Mavrakis

, Mylonakis

. Candida peritonitis: An update on the latest research and treatments. World J Surg, 2011; 35(12):2650–2659; doi: 10.1007/s00268-011-1305-2

Tracy

, Ward

, Durr

, et al. Antifungal prophylaxis after operative repair of traumatic gastric injuries does not correlate with better outcomes. J Am Coll Surg, 2020; 231(4):e226; doi: 10.1016/j.jamcollsurg.2020.08.605

10.

Gochi

, Rafaqat

, Panossian

, et al. Surgical infection society multi-center observational study: Empiric anti-fungal coverage after non-colonic gastrointestinal perforation. Surg Infect (Larchmt), 2025; 26(8):618–626; doi: 10.1089/sur.2024.306

11.

Huston

, Kreiner

, Ho

, et al. Role of empiric anti-fungal therapy in the treatment of perforated peptic ulcer disease: Review of the evidence and future directions. Surg Infect (Larchmt), 2019; 20(8):593–600; doi: 10.1089/sur.2019.062

12.

, Lee

, Liu

. Antifungal therapy did not improve outcomes including 30-day all-cause mortality in patients suffering community-acquired perforated peptic ulcer-associated peritonitis with Candida species isolated from their peritoneal fluid. J Microbiol Immunol Infect, 2017; 50(3):370–376; doi: 10.1016/j.jmii.2015.07.004

13.

Horn

, Coleoglou Centeno

, Rasane

, et al. Pre-operative anti-fungal therapy does not improve outcomes in perforated peptic ulcers. Surg Infect (Larchmt), 2018; 19(6):587–592; doi: 10.1089/sur.2018.058

14.

Montravers

, Mira

, Gangneux

, et al.; AmarCand study group. A multicentre study of antifungal strategies and outcome of Candida spp. Peritonitis in intensive-care units. Clin Microbiol Infect, 2011; 17(7):1061–1067; doi: 10.1111/j.1469-0691.2010.03360.x

15.

Pramod

, Vijayakumar

, Srinivasan

, et al. Clinical significance of Candida in an intraoperative peritoneal specimen with perforation peritonitis: An institutional perspective. Cureus, 2018; 10(3):e2275; doi: 10.7759/cureus.2275

16.

Taddei

, Giovannenze

, Birocchi

, et al. Empiric antifungal therapy for intra-abdominal post-surgical abscesses in non-ICU patients. Antibiotics (Basel), 2023; 12(4):701; doi: 10.3390/antibiotics12040701

17.

Tarasconi

, Coccolini

, Biffl

, et al. Perforated and bleeding peptic ulcer: WSES guidelines. World J Emerg Surg, 2020; 15:3; doi: 10.1186/s13017-019-0283-9

18.

Sartelli

, Chichom-Mefire

, Labricciosa

, et al. The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intra-abdominal infections. World J Emerg Surg, 2017; 12:29; doi: 10.1186/s13017-017-0141-6

19.

Savino

, Agarwal

, Wry

, et al. Routine prophylactic antifungal agents (clotrimazole, ketoconazole, and nystatin) in nontransplant/nonburned critically ill surgical and trauma patients. J Trauma, 1994; 36(1):20–26; doi: 10.1097/00005373-199401000-00004

20.

Kronen

, Liang

, Bochicchio

, et al. Invasive fungal infections secondary to traumatic injury. Int J Infect Dis, 2017; 62:102–111; doi: 10.1016/j.ijid.2017.07.002

21.

Fisher

, Alastruey-Izquierdo

, Berman

, et al. Tackling the emerging threat of antifungal resistance to human health. Nat Rev Microbiol, 2022; 20(9):557–571; doi: 10.1038/s41579-022-00720-1

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.01 MB